Alnylam Announces New Positive Interim Phase 1 Study Results for Fitusiran, a Once-Monthly, Subcutaneous, Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia and Ra

Go back to Alnylam Announces New Positive Interim Phase 1 Study Results for Fitusiran, a Once-Monthly, Subcutaneous, Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia and Ra
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Delayed: 176.89 +4.64 (2.69%)
Previous Close $172.25    52 Week High $109.10 
Open $170.42    52 Week Low $31.38 
Day High $177.53    P/E N/A 
Day Low $169.97    EPS $-1.45 
Volume 1,522,882